Sugi Predict

Sugi Predict / Compounds / SCHEMBL1009587

SCHEMBL1009587

SCHEMBL1009587

CC(C)(C)OC(=O)N1CCCCC1CCN

nearest known ligand 0.47

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ PDE8B O95263 1/20 0.47
▸ ATM Q13315 2/20 0.47
▸ CHEK2 O96017 1/20 0.43
▸ KDM1A O60341 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.42
▸ HPGD P15428 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ EPHX1 P07099 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.39
▸ PREP P48147 1/20 0.38
▸ OPRD1 P41143 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31037649 1.00 PDE8B (0.47) PDE8BATMCHEK2KDM1AHSD17B10
SCHEMBL23015233 1.00 PDE8B (0.47) PDE8BATMCHEK2KDM1AHSD17B10
SCHEMBL1427736 0.95 HSD17B10 (0.46) PDE8BATMCHEK2HSD17B10SMN1; SMN2
SCHEMBL1061613 0.95 HSD17B10 (0.46) PDE8BATMCHEK2HSD17B10SMN1; SMN2
SCHEMBL86228 0.95 HSD17B10 (0.46) PDE8BATMCHEK2HSD17B10SMN1; SMN2
SCHEMBL16012113 0.92 PDE8B (0.46) PDE8BATMCHEK2KDM1AHSD17B10
SCHEMBL4574708 0.89 ATM (0.42) PDE8BATMHSD17B10HPGDSMN1; SMN2
SCHEMBL31420888 0.89 ATM (0.42) PDE8BATMHSD17B10HPGDSMN1; SMN2
SCHEMBL7923096 0.89 ATM (0.42) PDE8BATMHSD17B10HPGDSMN1; SMN2
SCHEMBL80021 0.88 PDE8B (0.49) PDE8BATMCHEK2KDM1AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115894447-B METTL3 inhibitors and uses thereof 成都先导药物开发股份有限公司 2024-10-01 — — CN disclosed
EP-4298095-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITOR AND USES THEREOF Sperogenix Therapeutics Limited (HK) 2024-01-03 — — EP disclosed
CN-115894447-A METTL3 inhibitors and uses thereof 成都先导药物开发股份有限公司 2023-04-04 — — CN disclosed
US-20220388962-A1 MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS FOX CHASE CHEMICAL DIVERSITY CENTER INC. 2022-12-08 — — US disclosed
US-20220289753-A1 SHP2 INHIBITORS IRBM S.P.A. (IT) 2022-09-15 — — US disclosed
WO-2022162606-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITOR AND USES THEREOF SPEROGENIX THERAPEUTICS LIMITED (CN) 2022-08-04 — — WO disclosed
EP-4017492-A1 MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS Biohaven Therapeutics Ltd. (US) 2022-06-29 — — EP disclosed
CN-114667145-A Molecules that bind to TDP-43 for the treatment of amyotrophic lateral sclerosis and related disorders 拜尔哈文制药股份有限公司 2022-06-24 — — CN disclosed
CN-107709301-B Pyrazole derivative or pharmacologically acceptable salt thereof 橘生药品工业株式会社 2021-06-22 — — CN disclosed
WO-2021035101-A1 MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS BIOHAVEN THERAPEUTICS LTD. (US) 2021-02-25 — — WO disclosed
WO-2005010009-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2005-02-03 — — WO disclosed
US-20050020619-A1 Thienopyridine kinase inhibitors ABBOTT LABORATORIES 2005-01-27 — — US disclosed
US-20040209878-A1 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors SCHERING CORPORATION AND PHARMACOPEIA, INC. 2004-10-21 — — US disclosed
US-6806279-B2 FOR THERAPY OF AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS, MULTIPLE SCLEROSIS, UVEITIS, AND PSORIASIS, ALLOGRAFT REJECTION, AND GRAFT-VERSUS-HOST DISEASE SUNESIS PHARMACEUTICALS, INC. 2004-10-19 — — US disclosed
WO-2004022561-A1 PYRAZOLOPYRIMIDINES AS CYCLIN-DEPENDENT KINASE INHIBITORS SCHERING CORPORATION (US) 2004-03-18 — — WO disclosed
US-20030225131-A1 Thrombin inhibitors BURGEY CHRISTOPHER S (US) 2003-12-04 — — US disclosed
US-20030149049-A1 Small-molecule inhibitors of interleukin-2 SUNESIS PHARMACEUTICALS, INC. 2003-08-07 — — US disclosed
WO-2003051797-A2 SMALL-MOLECULE INHIBITORS OF INTERLEUKIN-2 SUNESIS PHARMACEUTICALS, INC. (US) 2003-06-26 — — WO disclosed
EP-1056733-A1 HISTAMINE H3 RECEPTOR LIGANDS JAMES BLACK FOUNDATION LIMITED (GB) 2000-12-06 — — EP disclosed
WO-1999042458-A1 HISTAMINE H3 RECEPTOR LIGANDS JAMES BLACK FOUNDATION LIMITED (GB) 1999-08-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220388962-A1 MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS TARDBP, TDP1, TDP2 PDE8B 4166/4885ATM 1914/4885CHEK2 3015/4885
US-20050020619-A1 Thienopyridine kinase inhibitors ABL1, MAP4K2, MAP4K5 PDE8B 1463/4885ATM 471/4885CHEK2 71/4885
US-20220289753-A1 SHP2 INHIBITORS PTPN1, PTPN2, PTPN7 PDE8B 1857/4885ATM 1978/4885CHEK2 1816/4885
US-20030225131-A1 Thrombin inhibitors TFPI, SERPINC1, PLAT PDE8B 970/4885ATM 3841/4885CHEK2 4055/4885
US-20030149049-A1 Small-molecule inhibitors of interleukin-2 IL2, IL2RA, HLA-DRB1 PDE8B 1449/4885ATM 4790/4885CHEK2 3678/4885
US-20040209878-A1 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors CDK2, CDK1, CDK5 PDE8B 1214/4885ATM 439/4885CHEK2 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.